Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
NCT ID: NCT04168099
Last Updated: 2019-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
60 participants
INTERVENTIONAL
2018-12-01
2028-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
NCT02120196
Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis
NCT02388035
Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin
NCT06234046
Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?
NCT02443285
Meropenem vs Cefotaxime as Empirical Treatment of SBP
NCT05427747
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cefotaxime
Cefotaxime intravenous
Cefotaxime
Cefotaxime IV
Gemifloxacin
Oral Gemifloxacin
Gemifloxacin
Gemifloxacin oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cefotaxime
Cefotaxime IV
Gemifloxacin
Gemifloxacin oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hala Shaaban El Gendy, Msc
Role: PRINCIPAL_INVESTIGATOR
Tanta University - Faculty of Medicine
Osama El Sayed Negm, Prof.
Role: PRINCIPAL_INVESTIGATOR
Tropical Medicine Dept.-Tanta University - Faculty of Medicine
Sherief Abd-Elsalam, Ass. Prof.
Role: PRINCIPAL_INVESTIGATOR
Tropical Medicine Dept.-Tanta University - Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sherief Abd-Elsalam
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SBP new treatment
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.